Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04641871 · ClinicalTrials.gov registry record · Phase 1
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
A Phase 1 study, sponsored by Symphogen A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT04641871 is a Phase 1 study that has completed, run by Symphogen A/S. The registered enrollment target is 78 participants.
The verdict
NCT04641871, a Phase 1 study, has completed, sponsored by Symphogen A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
The study will evaluate the preliminary efficacy of 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan) in patients with biliary tract carcinomas (BTC) and with esophageal squamous cell carcinoma (ESCC) by assessing overall response rates (ORRs) per Investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 The study will also evaluate the safety and tolerability profile of the 3 combinations
Interventions
- DRUG Irinotecan Hydrochloride
- DRUG Sym023
- DRUG Sym021
- DRUG Sym022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2020-10-12 |
| Est. Completion | 2024-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04641871
The ClinicalTrials.gov registry entry for NCT04641871 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Symphogen A/S, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Irinotecan Hydrochloride is the first listed.
NCT04641871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04641871 about?
NCT04641871 is a clinical study titled "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies". The study will evaluate the preliminary efficacy of 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan) in patients with biliary tract carcinomas (BTC) and with esophageal squamous cell carcinoma (ESCC) by assessing overall response rates (ORRs) per Investigator assessment usi...
What is the current status of trial NCT04641871?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2020-10-12. Estimated completion is 2024-06-03.
What interventions are being tested in trial NCT04641871?
The interventions under investigation include: Irinotecan Hydrochloride (DRUG), Sym023 (DRUG), Sym021 (DRUG), Sym022 (DRUG).
Who is sponsoring clinical trial NCT04641871?
This trial is sponsored by Symphogen A/S, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.